Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19.

Vuorio, Alpo; Raal, Frederick; Klingel, Reinhard; Kovanen, Petri T

Vuorio, Alpo; Raal, Frederick; Klingel, Reinhard; Kovanen, Petri T.

Vuorio A; Mehiläinen Airport Health Centre, Vantaa, Finland; Department of Forensic Medicine, University of Helsinki, Helsinki, Finland. Electronic address: alpo.vuorio@gmail.com.
Raal F; Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.
Klingel R; Apheresis Research Institute, Cologne, Germany; 1(st) Department of Internal Medicine, University of Mainz, Mainz, Germany.
Kovanen PT; Wihuri Research Institute, Helsinki, Finland.

J Clin Lipidol ; 15(2): 379-380, 2021.

Article in English | MEDLINE | ID: covidwho-1260768

Subject(s)

Blood Component Removal; COVID-19; Hyperlipoproteinemia Type II; Homozygote; Humans; Hyperlipoproteinemia Type II/genetics; Hyperlipoproteinemia Type II/therapy; Life Style; Lipoproteins; Pandemics; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Blood Component Removal / COVID-19 / Hyperlipoproteinemia Type II Limits: Humans Language: English Journal: J Clin Lipidol Journal subject: Biochemistry / Metabolism Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google